HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer

Breast Cancer Clinical Trial

Official title:

Randomized, Double-Blind, Vehicle-Controlled Pilot Study of the Efficacy and Safety of HylaCareTM in the Treatment of Acute Skin Changes in Patients Undergoing External Beam Radiotherapy for Tumors of the Breast.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02165605
• Other study ID #: STU 092012-058
• Status: Completed
• Phase: N/A
• Start date: August 2012
• Est. completion date: December 2015

Study information

• Verified date: September 2020
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a randomized, double blind, vehicle-controlled evaluation of the effectiveness and safety of HylaCareTM. The study will employ the patient as her own control, a commonly used method for the evaluation of topical dermatologic agents. Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily.

Description:

Patients will be allocated to the treatment using a randomized permuted block. There will be no stratification. Patients will be randomized to receive the investigational product to be applied to either the medial (inside) or lateral (outside) portion of the breast, a placebo product will be used on the other side. Patients and clinical investigators will be blinded to the treatment assignments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: December 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Female, age 18 or older

• Diagnosis of breast cancer

• Intact breast (not surgically absent)

• Planned fractionated external beam radiotherapy to be delivered by opposing, tangential beams to 50.4 Gy in 28 fractions with a planned photon or electron boost of 10Gy in 5 fractions (for a total of 33 fractions)

• Ability to understand and comply with the requirements of this study

• Ability to give Informed Consent

• For sexually active females, patient agrees to use acceptable method of birth control

Exclusion Criteria:

• Women who are pregnant or lactating

• Use of concomitant skin care preparations at any of the treated or control portal areas to be observed

• Any infection or unhealed wound of the radiotherapy portal areas, or generalized dermatitis

• Severe renal failure creatinine > 3.0 within 6 months of study registration

• Allergic history, including anaphylaxis or severe allergies to products in study serum or placebo

• Planned relocation which would make follow-up visits impossible during the course of the study

• Collagen vascular disease such as Lupus, or scleroderma

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• HylaCare
cream
• Placebo
placebo

Locations

Country	Name	City	State
United States	University of Texas Southwestern Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute Skin Toxicity Per NCI-CTC v4.0	NCI-CTC (National Cancer Institute-Common Terminology Criteria) version 4.0 was used to assessed acute skin toxicity grade by physician. Toxicity grade range from Grade 0 to Grade 5, with higher grade indicating worst skin toxicity.	Week 5 during radiation therapy
Primary	Acute Skin Toxicity Per NCI-CTC v4.0	NCI-CTC(National Cancer Institute-Common Terminology Criteria) version 4.0 was used to assessed acute skin toxicity grade by physician. Toxicity grade range from Grade 0 to Grade 5, with higher grade indicating worst skin toxicity.	Week 2 post-radiation therapy
Primary	Acute Skin Toxicity Per Investigator Grading Scale	Investigator Grading Scale is used to assessed acute skin toxicity. Score range from grade 0 to 6 with 0 = normal skin; = light epidermal irritation, consisting of the onset of erythema, possibly associated with slight edema; = erythema with dry desquamation; = wet desquamation = wet desquamation from 2.1 - 5cm; = wet desquamation from 5.1 - 9 cm; = wet desquamation > 9.1 cm	Week 5 during radiation therapy
Primary	Acute Skin Toxicity Per Investigator Grading Scale	Investigator Grading Scale is used to assessed acute skin toxicity. Score range from grade 0 to 6 with; 0 = normal skin; = light epidermal irritation, consisting of the onset of erythema, possibly associated with slight edema; = erythema with dry desquamation; = wet desquamation = wet desquamation from 2.1 - 5cm; = wet desquamation from 5.1 - 9 cm; = wet desquamation > 9.1 cm	Week 2 post-radiation therapy
Secondary	Acute Skin Toxicity, as Measured by Number of Participants With Skin Reactions	Acute skin toxicity, as measured by number of participants with skin reactions via self assessment	Week 5 during radiation therapy